Investors Investors

Stock Quote

Stock Quote

1:21 AM EDT on Jun 23

Press Releases

Press Releases

All Releases
Jun 04, 2018

NEW YORK , June 04, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced updated overall survival data from the Company’s pivotal Phase 2 trial of its targeted,

May 31, 2018

NEW YORK , May 31, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, announced today that Mark R. Baker , Chief Executive Officer, will present at the Jefferies 2018

May 31, 2018

NEW YORK , May 31, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, announced today that an abstract describing the Company’s imaging analysis technology will be

May 22, 2018

Data Support Prognostic Utility of aBSI as an Imaging Biomarker for Survival in Patients with Castration-Resistant Prostate Cancer NEW YORK , May 22, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that results from a trial evaluating the use of its automated

May 09, 2018

Pre-Commercial Launch Preparations Underway for AZEDRA ® (iobenguane I 131) ahead of U.S. Food and Drug Administration ( FDA ) July 30 th Action Date Top-Line Data from Phase 3 Trial for PSMA-Targeted SPECT/CT Imaging Agent 1404 Expected in Q3’18 Enrollment Expected to Complete in Phase 2/3 Trial

May 02, 2018

RELISTOR® Injection Protected from Generic Competition Until 2024 NEW YORK , May 02, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) reported that its partner Valeant Pharmaceuticals International, Inc. today announced that the U.S.

Apr 26, 2018

NEW YORK , April 26, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that it will host a conference call and webcast to review the first

Apr 25, 2018

Pivotal Phase 2 AZEDRA Data Selected for Oral Presentation NEW YORK , April 25, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, today announced that two

Apr 02, 2018

NEW YORK , April 02, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that Mark R. Baker , Chief Executive Officer, will present at the H.C.

Mar 22, 2018
NEW YORK , March 22, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that the Company has received notification from the U.S.
Mar 20, 2018
NEW YORK , March 20, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that Mark R. Baker , Chief Executive Officer, will present at the 17th
Mar 19, 2018
Significant correlation between overall tumor biomarker response and achievement of the primary and secondary endpoints in pivotal study of AZEDRA NEW YORK , March 19, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and
Mar 08, 2018
Company Preparing for Potential Commercial Launch of AZEDRA® (iobenguane I 131) Ahead of U.S. Food and Drug Administration ( FDA ) April 30th Action Date Enrollment Complete in Phase 3 Trial for PSMA-Targeted SPECT/CT Imaging Agent 1404; Top-Line Results Anticipated in Q3’18 Enrollment Ongoing in
Mar 01, 2018
NEW YORK , March 01, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that it will host a conference call and webcast to review the fourth
Feb 15, 2018
NEW YORK , Feb. 15, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that Mark R. Baker , Chief Executive Officer, will present at the 2018
Feb 05, 2018
NEW YORK , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that Patrick Fabbio , Chief Financial Officer, will present at the 2018 BIO
Feb 01, 2018
NEW YORK , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, today announced that data from the Company’s open-label pivotal Phase 2b study of AZEDRA ®
Jan 02, 2018
Top-line Data Expected in 3Q2018 NEW YORK , Jan. 02, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, today announced that it has completed enrollment in its
Dec 29, 2017
NEW YORK , Dec. 29, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that the U.S. Food and Drug Administration ( FDA ) has accepted for review
Nov 02, 2017
NDA (New Drug Application) for AZEDRA ® (iobenguane I 131) Submitted to the U.S. Food and Drug Administration ( FDA ) on October 31 st Positive Results from the Pivotal Phase 2b Study of AZEDRA Highlighted at Multiple Medical Conferences Clinical Trials for Prostate Cancer Product Candidates